Breast: Metastatic Clinical Trials

Showing 31-36 of 36 items
31.
32.
33.
34.
35.
36.
  • Study of SRN-927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
  • This is an open-label, dose-finding study of SRN-927 administered orally on a continuous daily dosing regimen with a PK lead-in period (dose escalation period only). The incidence of dose limiting toxicity (DLT) will be evaluated from Day -7 through the first cycle (28 days) of treatment (35 days total). Depending on safety and tolerability, patients will be assigned sequentially to escalating doses of SRN-927 using standard 3+3 design. All patients will be treated until disease progression, unacceptable toxicity, or patient withdrawal of consent.
  • Diagnoses: Breast: Metastatic
  • Status: Recruiting
Showing 31-36 of 36 items
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms